Monoclonal gammopathy of undetermined significance classification: Difference between revisions
| Line 1: | Line 1: | ||
'''Editor-In-Chief:''' [[User:C Michael Gibson|C. Michael Gibson, M.S., M.D.]] [[Mailto:charlesmichaelgibson@gmail.com|[1]]]; '''Associate Editor(s)-in-Chief:''' [[User:Okamal|Omer Kamal, M.D.]] [[Mailto:okamal@bidmc.harvard.edu|[2]]] | |||
__NOTOC__ | __NOTOC__ | ||
{{Monoclonal gammopathy of undetermined significance }} | {{Monoclonal gammopathy of undetermined significance }} | ||
| Line 7: | Line 9: | ||
OR | OR | ||
Monoclonal gammopathy of undetermined significance (MGUS) may be classified according to cytogenetic differences into the following subtypes/groups:<ref name="pmid20884827" /> | |||
OR | OR | ||
| Line 30: | Line 32: | ||
== Classification[edit | edit source] == | == Classification[edit | edit source] == | ||
Monoclonal gammopathy of undetermined significance (MGUS) may be classified according to cytogenetic differences into the following subtypes/groups:<ref name="pmid20884827">{{cite journal |vauthors=Rajkumar SV, Kyle RA, Buadi FK |title=Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence |journal=Mayo Clin. Proc. |volume=85 |issue=10 |pages=945–8 |date=October 2010 |pmid=20884827 |pmc=2947967 |doi=10.4065/mcp.2010.0520 |url=}}</ref> | |||
{| class="wikitable" | |||
|Abnormalities in cytogenes | |||
|Affected genes | |||
|- | |||
|'''IgH translocation:''' | |||
| | |||
|- | |||
|t(11;14), q(13;32) | |||
|cyclin D1 | |||
|- | |||
|t(4;14)(p16;q32) | |||
|FGFR-3, and MMSET | |||
|- | |||
|t(14;16)(q32;q23) | |||
|C-MAF | |||
|- | |||
|t(6;14)(q32;q11) | |||
|MAFB | |||
|- | |||
|'''IgH non-translocated :''' | |||
| | |||
|- | |||
|Hyper diploid | |||
|Numerous | |||
|} | |||
'''If the staging system involves specific and characteristic findings and features:''' | '''If the staging system involves specific and characteristic findings and features:''' | ||
Revision as of 15:50, 2 August 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [[1]]; Associate Editor(s)-in-Chief: Omer Kamal, M.D. [[2]]
|
Monoclonal gammopathy of undetermined significance Microchapters |
|
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Monoclonal gammopathy of undetermined significance classification On the Web |
|
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance classification |
|
FDA on Monoclonal gammopathy of undetermined significance classification |
|
on Monoclonal gammopathy of undetermined significance classification |
|
Monoclonal gammopathy of undetermined significance classification in the news |
|
Blogs on Monoclonal gammopathy of undetermined significance classification |
|
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
Overview[edit | edit source]
There is no established system for the classification of [disease name].
OR
Monoclonal gammopathy of undetermined significance (MGUS) may be classified according to cytogenetic differences into the following subtypes/groups:[1]
OR
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
Classification[edit | edit source]
Monoclonal gammopathy of undetermined significance (MGUS) may be classified according to cytogenetic differences into the following subtypes/groups:[1]
| Abnormalities in cytogenes | Affected genes |
| IgH translocation: | |
| t(11;14), q(13;32) | cyclin D1 |
| t(4;14)(p16;q32) | FGFR-3, and MMSET |
| t(14;16)(q32;q23) | C-MAF |
| t(6;14)(q32;q11) | MAFB |
| IgH non-translocated : | |
| Hyper diploid | Numerous |
If the staging system involves specific and characteristic findings and features:
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
References
- ↑ 1.0 1.1 Rajkumar SV, Kyle RA, Buadi FK (October 2010). "Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence". Mayo Clin. Proc. 85 (10): 945–8. doi:10.4065/mcp.2010.0520. PMC 2947967. PMID 20884827.